Top Page
MEDIROM Healthcare Technologies
(NASDAQ:MRM)
MEDIROM Healthcare Technologies (MRM) vs. SPDR S&P 500 ETF (SPY)
MEDIROM Healthcare Technologies Business Overview & Revenue Model
MEDIROM Healthcare Technologies Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.85B | 8.30B | 6.83B | 6.95B | 5.41B | 3.34B |
| Gross Profit | 1.67B | 2.25B | 1.57B | 1.90B | 1.42B | 428.95M |
| EBITDA | 825.29M | 387.50M | 310.08M | 373.63M | -276.29M | -551.16M |
| Net Income | 726.29M | 148.76M | 115.05M | 148.97M | -990.73M | -539.17M |
Balance Sheet | ||||||
| Total Assets | 55.36M | 8.09B | 6.85B | 6.75B | 5.75B | 5.71B |
| Cash, Cash Equivalents and Short-Term Investments | 268.75K | 335.56M | 132.85M | 605.95M | 377.12M | 1.47B |
| Total Debt | 27.12M | 3.96B | 3.65B | 3.23B | 2.79B | 2.56B |
| Total Liabilities | 51.91M | 6.90B | 6.63B | 6.81B | 5.96B | 5.22B |
| Stockholders Equity | 3.07M | 933.27M | 210.88M | -59.38M | -208.34M | 491.26M |
Cash Flow | ||||||
| Free Cash Flow | -1.09B | -1.90B | -767.58M | -806.44M | -652.88M | -439.98M |
| Operating Cash Flow | -548.33M | -1.33B | -631.74M | -685.70M | -557.23M | -366.42M |
| Investing Cash Flow | -402.10M | 361.39M | -328.58M | 580.44M | -83.94M | -139.60M |
| Financing Cash Flow | 1.13B | 1.19B | 461.21M | 340.10M | -427.95M | 1.43B |
MEDIROM Healthcare Technologies Technical Analysis
MEDIROM Healthcare Technologies Risk Analysis
MEDIROM Healthcare Technologies Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
58 Neutral | $10.75M | 3.74 | 48.22% | ― | 13.71% | ― | |
57 Neutral | $57.47M | 0.51 | 98.54% | ― | 13.98% | 34.14% | |
45 Neutral | $11.51M | -0.59 | ― | ― | ― | ― | |
40 Neutral | $45.63M | -0.01 | -1.75% | ― | -2.53% | 99.45% |
MEDIROM Healthcare Technologies Corporate Events
On January 23, 2026, MEDIROM Healthcare Technologies Inc. signed a Master Service Agreement with Tools for Humanity and the World Foundation to support large-scale adoption of World ID in Japan by installing Orb biometric authentication devices at around 3,000 locations nationwide, a major increase from an initial plan of roughly 100 sites. The company will leverage its Re.Ra.Ku wellness salon network—where Orbs are already installed at more than 150 centers with a target of about 300—and a broader management partner network that includes Japan Relaxation Industry Association members and other retailers, with 370 third-party locations already under negotiation, establishing a new special mission team and standardized framework for contracts, branding, privacy protection and quality control to drive consistent authentication services and deepen its role in Japan’s digital identity and HealthTech ecosystem.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
On January 8, 2026, MEDIROM Healthcare Technologies announced that its collaboration with World, the Proof of Human authentication protocol co-founded by Sam Altman and Alex Blania, helped drive the cumulative number of World ID “Orb” authentications at Re.Ra.Ku‑centered salons in Japan past 20,000 as of December 28, 2025, roughly doubling the tally in about two months since hitting 10,000 on October 23, 2025. The company attributed this rapid growth to the synergistic combination of World’s digital identity vision with MEDIROM’s nationwide physical store network and to its 25th‑anniversary “5‑Minute Shoulder Massage Campaign for 250,000 People,” which drew customers into stores for free massages while they waited to verify their humanness, and said it plans to further expand Orb installations to 200 salons to deepen its role in building new digital social infrastructure that links wellness services with emerging identity technology in Japan.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
On December 29, 2025, MEDIROM Healthcare Technologies announced it had signed a Master Service Agreement with Tools for Humanity and the World Foundation to build and operate a “Proof of Human” verification network in Japan, based on the World project co-created by Sam Altman and Alex Blania. Leveraging its nationwide footprint of about 300 wellness locations, the company will host World’s Orb devices and run dedicated verification sites and pop-up locations, under a newly formed MEDIROM World Proof of Human Task Force, with the initiative expected to generate operational-fee revenue and position MEDIROM as a key infrastructure partner in Japan’s emerging digital identity and AI-era authentication market.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
On December 22, 2025, MEDIROM Healthcare Technologies reported key performance indicators for November 2025, highlighting solid salon economics despite a modest contraction in scale. The company operated 294 salons, with data from 273 locations showing 67,800 customers served in the month, average sales per customer of ¥7,621—around ¥2,815 above the sector’s estimated average—and an improved customer repeat ratio of 79.4%, up 1.9 percentage points year-on-year, alongside an operation ratio of 43.9%. While total customers served and the number of salons declined versus the prior year, the higher spend per visit and stronger loyalty metrics underline a shift toward higher-value, more stable customer relationships, reinforcing MEDIROM’s positioning in Japan’s relaxation salon market.
In its health-tech business, the company reported continued expansion of its Lav®-based remote specific health guidance program, which targets individuals aged 40–74 at risk of lifestyle-related diseases and is sold to corporate insurance associations amid government-backed efforts to raise national checkup and guidance participation rates. As of November 2025, MEDIROM had contracts with 102 corporate insurance associations and a cumulative 12,020 Lav® users, up from 96 associations and 8,515 users a year earlier, underscoring steady penetration of ICT-driven preventive health solutions as insurers and policymakers push to close the gap with national implementation targets.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
On December 12, 2025, MEDIROM Healthcare Technologies Inc. completed the sale and issuance of JPY400,000,000 in convertible corporate bonds to 11 investors. The proceeds will be used for general corporate and financing purposes. The bonds were issued outside the United States under Regulation S, and are not registered under the Securities Act, limiting their offer and sale within the U.S. This strategic move is expected to support the company’s financial flexibility and operational growth.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
On December 11, 2025, MEDIROM Healthcare Technologies Inc. announced the issuance of its Third Unsecured Convertible-Type Corporate Bonds with Share Options, totaling 400,000,000 JPY. The bonds, issued through a third-party allotment, are set to close on December 12, 2025, and offer a 2.0% annual interest rate with a maturity date of June 30, 2026. These bonds can be converted into common shares, providing flexibility for investors. The proceeds are intended for general corporate purposes, potentially enhancing the company’s financial position and strategic capabilities. This move reflects MEDIROM’s efforts to strengthen its market presence and operational capacity.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
On December 4, 2025, MEDIROM Healthcare Technologies Inc. announced a strategic partnership with TD SYNNEX K.K. to enhance the national distribution of the MOTHER Bracelet and REMONY health monitoring system. This collaboration aims to leverage TD SYNNEX’s extensive sales network to accelerate the adoption of these innovative health-tech solutions across Japan, potentially strengthening MEDIROM’s market position and offering significant benefits to stakeholders by improving health management and safety solutions.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
On December 3, 2025, MEDIROM Healthcare Technologies Inc. announced its updated Key Performance Indicators (KPIs) for October 2025. The company reported serving 69,669 customers with a sales per customer figure of JPY 7,445, significantly higher than the industry average. The customer repeat ratio improved to 77.8%, indicating strong customer loyalty. The company operates 295 salons, with 273 providing comparable data. In its health tech business, MEDIROM has contracts with 101 corporate insurance associations, and its Lav® app has over 11,000 users, reflecting growth in the health guidance market.
The most recent analyst rating on (MRM) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.